CCND1 and Miyoshi myopathy: With evidence pointing to a capacity for reciprocal D-type cyclin substitution in MM under trametinib treatment, the fundamental function of cyclin D2 in compensating for diminished cyclin D1 in early trametinib resistance was examined.